Immune Profiles Evolution Under Immunotherapy for Melanoma
About this study
The primary objective of the study aims to compare the immune profiles (circulating cytokines and lymphocytes) before and after (6 to 8 weeks) the first infusion of immune checkpoint inhibitors in patients with melanoma treated in the adjuvant setting(cohort A) or in metastatic setting(cohort B); and to study the association of these immune profiles with relapse- or progression-free survival.
- Condition
- Melanoma
- Tested
- venous puncture, tumoral biopsy
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 7
- Minimum age: 18 years
- Study condition: Melanoma
- Patient aged ≥ 18 years;
- Totally resected stage III or IV melanoma totally resected, treated with a immune therapy (pembrolizumab or nivolumab ou other immune checkpoint inhibitors) as adjuvant treatment;
- Unresectable stage IIIC/D or IV metastatic melanoma, treated with immune therapy (pembrolizumab or nivolumab or immune checkpoint inhibitors) which should be associated by a radiotherapy ;
- Patient has been informed about the study and signed the consent;
- Affiliated to the French social security scheme.
Exclusion 6
- Pregnant or breastfeeding woman;
- Patient refusal;
- Patient receiving a immunosuppressor;
- Undergo a general corticotherapy of \> 10 mg/kg/day since more than 7 days;
- Patient who participate to another blind interventional study receiving blinded treatment;
- Patient without any social protection by organization.
Where
1 site, 1 recruiting
Dermato-oncology department, Ambroise Paré hospital, APHP
Boulogne-Billancourt, France
Contact
-
Elisa FUNCK-BRENTANO, MD
+33 (0)1 71 16 77 21 elisa.funck-brentano@aphp.fr
Potential match only. Final eligibility is determined by the study team.